Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
TRPA1 Biologics Sequence Review Report 2026: Transient receptor potential cation channel subfamily A member 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TRPA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TRHR Biologics Sequence Review Report 2026: Thyrotropin-releasing hormone receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TRHR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TRBC1 Biologics Sequence Review Report 2026: T cell receptor beta constant 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TRBC1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TRB Biologics Sequence Review Report 2026: T cell receptor beta chain MC.7.G5 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TRB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TRA Biologics Sequence Review Report 2026: T cell receptor alpha chain MC.7.G5 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TRA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TRAC Biologics Sequence Review Report 2026: T cell receptor alpha chain constant Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TRAC protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TBXA2R Biologics Sequence Review Report 2026: Thromboxane A2 receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TBXA2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TIE1 Biologics Sequence Review Report 2026: Tyrosine-protein kinase receptor Tie-1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TIE1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TARM1 Biologics Sequence Review Report 2026: T-cell-interacting, activating receptor on myeloid cells protein 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TARM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TACR3 Biologics Sequence Review Report 2026: Neuromedin-K receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TACR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TACR1 Biologics Sequence Review Report 2026: Substance-P receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TACR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TACR2 Biologics Sequence Review Report 2026: Substance-K receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TACR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.